Table 2. Orthogonal testing results with two SARS-CoV-2 IgG assays, Ontario, Canada, March–June 2020 (n = 8,902).
| Anti-SARS-CoV-2 IgG assay | Abbott Architect assay | Total | |||
|---|---|---|---|---|---|
| Positive (n) | Negative (n) | n | % | ||
| Ortho-Diagnostics VITROS assay | Positive (n) | 97 | 0 | 97 | 1.1 |
| Negative (n) | 34 | 0 | 34 | 0.4 | |
| Not retested (n) | 0 | 8,771 | 8,771 | 98.5 | |
| Total (n) | 131 | 8,771 | 8,902 | 100 | |
SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.
The tests used were the Abbott Architect SARS-CoV-2 IgG assay (Abbott Laboratories, Abbott Park, Illinois, US), which detects anti-nucleocapsid antibodies, and the VITROS anti-SARS-CoV-2 IgG assay (Ortho-Clinical Diagnostics, Raritan, New Jersey, US), which detects anti-spike antibodies.